The Antipsychotic Discontinuation in Alzheimer Disease Trial: Clinical Rationale and Study Design


      Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients with psychosis or agitation receive open treatment with risperidone for 16 weeks. Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks.


      Several design features provide unique strengths to this trial: identification of target symptoms and systematic open antipsychotic treatment with only responders randomized in the discontinuation trial, use of a single antipsychotic medication, two clinically relevant time-points for discontinuation to evaluate the impact of duration of treatment on relapse, exclusion of patients at increased risk of stroke, assessment of several affected symptom domains, and state-of-the-art approaches to assess relapse and handle dropout.


      This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment. Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Geriatric Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Devanand DP
        • Jacobs DM
        • Tang M-X
        • et al.
        The course of psychopathologic symptoms in mild to moderate Alzheimer's disease.
        Arch Gen Psychiatry. 1997; 54: 257-263
        • Lyketsos CG
        • Steinberg M
        • Tschanz
        • et al.
        Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.
        Am J Psychiatry. 2000; 157: 708-714
        • Scarmeas N
        • Brandt J
        • Blacker D
        • et al.
        Disruptive behavior as a predictor in Alzheimer disease.
        Arch Neurol. 2007; 64: 1755-1761
        • Holm A
        • Michel M
        • Stern GA
        • et al.
        The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors.
        Gerontologist. 1999; 39: 668-676
        • Rovner BW
        • Steele CD
        • Shmuely Y
        • et al.
        A randomized trial of dementia care in nursing homes.
        J Am Geriatr Soc. 1996; 44: 7-13
        • Kong EH
        • Evans LK
        • Guevara JP
        Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis.
        Aging Ment Health. 2009; 13: 512-520
        • Ballard C
        • Brown R
        • Fossey J
        • et al.
        Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD trial).
        Am J Geriatr Psychiatry. 2009; 17: 726-733
        • Schneider LS
        • Dagerman K
        • Insel PS
        Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
        Am J Geriatr Psychiatry. 2006; 14: 191-210
        • Katz I
        • de Deyn PP
        • Mintzer J
        • et al.
        The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
        Int J Geriatr Psychiatry. 2007; 22: 475-484
        • Devanand DP
        • Marder K
        • Michaels KS
        • et al.
        A randomized, placebo-controlled, dose-comparison trial of haloperidol treatment for psychosis and disruptive behaviors in Alzheimer's disease.
        Am J Psychiatry. 1998; 155: 1512-1520
        • DeDeyn PP
        • Rabheru K
        • Rasmussen A
        • et al.
        A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.
        Neurology. 1999; 53: 946-955
        • Katz IR
        • Jeste DV
        • Mintzer JE
        • et al.
        Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial.
        J Clin Psychiatry. 1999; 60: 107-115
        • Street JW
        • Clark WS
        • Gannon KS
        • et al.
        Olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities.
        Arch Gen Psychiaty. 2000; 57: 2269-2276
        • Mintzer JE
        • Tune LE
        • Breder CD
        • et al.
        Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
        Am J Geriatr Psychiatry. 2007; 15: 918-931
        • Pollock BG
        • Mulsant BH
        • Rosen J
        • et al.
        A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
        Am J Geriatr Psychiatry. 2007; 15: 942-952
        • Jeste DV
        • Okamoto A
        • Napolitano J
        • et al.
        Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
        Am J Psychiatry. 2000; 157: 1150-1155
        • Schneider LS
        • Tariot PN
        • Dagerman KS
        • et al.
        CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
        New Engl J Med. 2006; 355: 1525-1538
        • Raivio MM
        • Laurie JV
        • Strandberg TE
        • et al.
        Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study.
        Am J Geriatr Psychiatry. 2007; 15: 416-424
        • Simoni-Wastila L
        • Ryder PT
        • Qian J
        • et al.
        Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities.
        Am J Geriatr Psychiatry. 2009; 17: 417-427
        • Avorn J
        • Soumerai SB
        • Everitt DE
        • et al.
        A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes.
        New Engl J Med. 1992; 327: 168-173
        • Fitz D
        • Mallya A
        Discontinuation of a psychogeriatric program for nursing home residents: psychotropic medication changes and behavioral reactions.
        J Appl Gerontol. 1992; 11: 50-63
        • Thapa PB
        • Meador KG
        • Gideon P
        • et al.
        Effects of antipsychotic withdrawal in elderly nursing home residents.
        J Am Geriatr Soc. 1994; 42: 280-286
        • Bridges-Parlet S
        • Knopman D
        • Steffes S
        Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a doubleblind baseline-treatment-controlled pilot study.
        J Geriatric Psych Neurol. 1997; 10: 119-126
        • Horwitz GJ
        • Tariot PN
        • Mead K
        • et al.
        Discontinuation of antipsychotics in nursing home patients with dementia.
        Am J Geriatr Psychiatry. 1995; 3: 290-299
        • Ruths S
        • Straand J
        • Nygaard HA
        • et al.
        Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized placebo-controlled double-blinded study. The Bergen District Nursing Home Study.
        J Am Geriatr Soc. 2004; 52: 1737-1743
        • Cohen-Mansfield J
        • Lipson S
        • Werner P
        • et al.
        Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.
        Arch Intern Med. 1999; 159: 1733-1740
        • Ballard CG
        • Thomas A
        • Fossey J
        • et al.
        A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
        J Clin Psych. 2004; 65: 114-119
        • Ballard C
        • Margallo LM
        • Theodoulou M
        • et al.
        A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DARTAD trial).
        PLoS Med. 2008; 5: e76
        • Sultzer DL
        • Davis SM
        • Tariot PN
        • CATIE-AD Study Group
        • et al.
        Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase A outcomes from the CATIE-AD effectiveness trial.
        Am J Psychiatry. 2008; 165 (Epub Jun 2, 2008): 844-854
        • Brodaty H
        • Ames D
        • Snowdon J
        • et al.
        A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
        J Clin Psychiatry. 2003; 64: 134-143
        • McKeith IG
        • Dickson DW
        • Lowe J
        • et al.
        Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium.
        Neurology. 2005; 65: 1992
        • Hamilton JM
        • Salmon DP
        • Galasko D
        • et al.
        Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.
        Neuropsychology. 2008; 22: 729-737
        • Fleiss JL
        • Levin B
        • Paik MC
        Statistical Methods for Rates and Proportions. 3rd ed. John Wiley & Sons, Hoboken, NJ2003
        • Cummings JL
        • Mega M
        • Gray K
        • et al.
        The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia.
        Neurology. 1994; 44: 2308-2314
        • Tariot PN
        • Salzman C
        • Yeung PP
        • et al.
        Long-term use of quetiapine in elderly patients with psychotic disorders.
        Clin Ther. 2000; 22: 1068-1084
        • Schneider LS
        • Olin JT
        Clinical global impressions in Alzheimer's clinical trials.
        Int Psychogeriatr. 1996; 8: 277-290
        • Simpson GM
        • Lee JH
        • Zoubok B
        • et al.
        A rating scale for tardive dyskinesia.
        Psychopharmacology. 1979; 64: 171-179
        • Folstein MF
        • Folstein SE
        • McHugh PR
        Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Peto R
        • Peto J
        • et al.
        Asymptotically efficient rank invariant procedures (with discussion).
        J.R. Statist Soc. 1972; 135: 185-207
        • Cox DR
        • Oakes D
        Analysis of survival data. Chapman and Hall, London1984
        • Rosenberg PB
        • Drye LT
        • Martin BK
        • et al.
        DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease.
        Am J Geriatr Psychiatry. 2010; 18: 136-145
        • Mohr JP
        • Thompson JL
        • Lazar RM
        • et al.
        Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
        N Engl J Med. 2001; 345: 1444-1451


        • Schneider LS
        • Dagerman KS
        • Insel P
        Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
        JAMA. 2005; 294: 1934-1943